Literature DB >> 6189579

Acute-phase reactant proteins and carcinoembryonic antigen in cancer of the colon and rectum.

C Walker, B N Gray.   

Abstract

One hundred and twenty-eight patients bearing primary malignancies of the large bowel were studied to ascertain the value of acute-phase reactant proteins (serum protein hexose, ceruloplasmin, transferrin, alpha-1-antitrypsin, seromucoid and haptoglobin) either alone or in conjunction with carcinoembryonic antigen to accurately reflect the disease status of patients both before and after resection of their large bowel malignancy. The results indicate that acute-phase reactant proteins have a higher diagnostic rate for the presence of malignancy than does CEA. Estimation of the serum protein hexose alone is of greater diagnostic value than a combination of acute-phase reactant proteins. Furthermore, serum protein hexose and CEA are complementary and when combined will reflect the presence of malignancy in a greater number of patients than either one alone. Following resection of primary large bowel cancer, acute-phase reactant proteins are as accurate as CEA in evaluating the disease-free status of patients and furthermore when combined with CEA increased the predictive value for the detection of patients with recurrent disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6189579     DOI: 10.1002/1097-0142(19830701)52:1<150::aid-cncr2820520127>3.0.co;2-0

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Serum levels of some acute phase proteins in kidney and urinary tract urothelial cancers.

Authors:  M Pejovic; V Djordjevic; I Ignjatovic; T Stamenic; V Stefanovic
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

2.  Immunosuppressive acidic protein in patients with brain tumours: a preliminary report.

Authors:  K Kikuchi; H Gotoh; M Kowada
Journal:  Acta Neurochir (Wien)       Date:  1987       Impact factor: 2.216

3.  N-glycoprotein SRMAtlas: a resource of mass spectrometric assays for N-glycosites enabling consistent and multiplexed protein quantification for clinical applications.

Authors:  Ruth Hüttenhain; Silvia Surinova; Reto Ossola; Zhi Sun; David Campbell; Ferdinando Cerciello; Ralph Schiess; Damaris Bausch-Fluck; George Rosenberger; Jingchung Chen; Oliver Rinner; Ulrike Kusebauch; Marián Hajdúch; Robert L Moritz; Bernd Wollscheid; Ruedi Aebersold
Journal:  Mol Cell Proteomics       Date:  2013-02-13       Impact factor: 5.911

4.  Serum glycoconjugates and ceruloplasmin in cancer of uterine cervix.

Authors:  Sharmila Upadhya; Subramanya Upadhya; K S Prabhu
Journal:  Indian J Clin Biochem       Date:  2002-01

5.  Mass-selected site-specific core-fucosylation of ceruloplasmin in alcohol-related hepatocellular carcinoma.

Authors:  Haidi Yin; Zhenxin Lin; Song Nie; Jing Wu; Zhijing Tan; Jianhui Zhu; Jianliang Dai; Ziding Feng; Jorge Marrero; David M Lubman
Journal:  J Proteome Res       Date:  2014-05-15       Impact factor: 4.466

6.  The role of a questionnaire and four biochemical markers to detect cancer risk in a symptomatic population.

Authors:  E M Chisholm; R J Marshall; D Brown; E H Cooper; G R Giles
Journal:  Br J Cancer       Date:  1986-01       Impact factor: 7.640

7.  Prediction of colorectal cancer diagnosis based on circulating plasma proteins.

Authors:  Silvia Surinova; Meena Choi; Sha Tao; Peter J Schüffler; Ching-Yun Chang; Timothy Clough; Kamil Vysloužil; Marta Khoylou; Josef Srovnal; Yansheng Liu; Mariette Matondo; Ruth Hüttenhain; Hendrik Weisser; Joachim M Buhmann; Marián Hajdúch; Hermann Brenner; Olga Vitek; Ruedi Aebersold
Journal:  EMBO Mol Med       Date:  2015-09       Impact factor: 12.137

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.